比利时,疫苗的先行者 Vaccines, a Belgian Specialty

比利时,疫苗的先行者 Vaccines, a Belgian Specialty

在欧委会批准辉瑞–BioNTech新冠疫苗后,比利时于12月28日启动新冠疫苗接种计划。首批疫苗已运往比利时境内的几家养老院。

 

作为药物研发枢纽,比利时积极研发和生产疫苗、药物及医疗产品,为全球抗击新冠疫情贡献力量。比利时拥有众多高校、科研中心和辉瑞、葛素兰史克(GSK)等国际药企巨头,从而使得比利时的企业和个人在疫苗研发方面发挥了突出作用。比利时强大的空运、航运和陆运能力也足以解决将医药产品运抵全球各地的挑战。

 

国际团结合作是抗疫的关键,正如我们发展合作部长Meryame Kitir所说:“只要还有一个国家遭受新冠疫情影响,那其他国家就无法幸免。”为此,比利时向“全球新冠疫苗获取机制”(COVAX)注资四百万欧元,以确保全球各个国家和地区均能获得疫苗。未来,比利时将继续在这一方面发挥先锋作用。

Belgium started its COVID-19 vaccination programme on 28 December, following the European Commission’s approval of the  Pfizer-BioNTech vaccine. Our first vaccines were sent out to a few rest  homes all over the country.

Belgium as a pharmaceutical hub also contributes to the global fight against COVID-19 in developing and producing vaccines,  drugs and medical products. The presence of the biggest pharma world  leaders –such as Pfizer and GSK–, universities  and research centres made it possible for Belgian companies and individuals to play a prominent role in the development of a vaccine.  Our unique aerial, maritime and terrestrial logistic capabilities are up  to the challenges of the distribution and transport  of pharma products around the world. 

International solidarity is key in fighting the epidemic. In the words of our Minister for Development Cooperation  Meryame Kitir: “No country in the world will be safe from COVID-19 as long as not all countries are safe.”. Belgium hence allocated 4 million euros to the COVAX initiative to contribute to making the vaccine available in every country in the world, and will continue to play a pioneering role in this endeavour.

Leave a Reply

Your email address will not be published. Required fields are marked *

seventeen + 7 =